title: Synthesis and biological evaluation of 18F-Norfallypride in the rodent brain using PET imaging.
abstract: Norfallypride (N-[(2-pyrolidinyl)methyl]-2,3-dimethoxy-5-(3'-fluoropropyl)benzamide), an analog of fallypride, has been synthesized and evaluated as a potential PET imaging agent for dopamine receptors with increased subtype selectivity. In order to synthesize (18)F-Norfallypride, the substituted benzamide tosylate (S)-N-[(1-BOC-2-pyrolidinyl)methyl]-2,3-dimethoxy-5-(3'-tosyloxypropyl)-benzamide) was radiolabeled with (18)F using Kryptofix and K2CO3 in acetonitrile and deprotected with trifluoroacetic acid to yield (S)-(18)F-Norfallypride in approx. 10% radiochemical yields. Norfallypride exhibited an IC50 of 0.63μM for displacing (18)F-fallypride in rat brain slices. In vitro rat brain autoradiographic studies revealed weak binding of (18)F-norfallypride to striatal regions. PET imaging in rats showed low brain uptake of (18)F-norfallypride in the rat brain. Ex vivo brain PET analysis displayed binding of (18)F-norfallypride in several brain regions. With respect to the cerebellum, ex vivo PET ratios were: striatum>3; hypothalamus>2; hippocampus~2; cerebellar nuclei >2 while autoradiographic ratios were 14, 9, 4 and 6 respectively. (18)F-Norfallypride exhibited a unique binding profile to rat brain regions known to contain significant amounts of dopamine D3 and serotonin 5HT3 receptors. Efforts are currently under way to increase brain permeability and fully characterize the binding of (18)F-norfallypride in vivo.
authors.affiliation: Department of Radiological Sciences, Preclinical Imaging, University of California, Irvine, CA 92697-5000, USA.
authors.forename: Neema
authors.initials: N
authors.lastname: Pithia
authors.forename: Neal
authors.initials: N
authors.lastname: Gulati
authors.forename: Suresh
authors.initials: S
authors.lastname: Pandey
authors.forename: Robert
authors.initials: R
authors.lastname: Coleman
authors.forename: Ritu
authors.initials: R
authors.lastname: Kant
authors.forename: Jogeshwar
authors.initials: J
authors.lastname: Mukherjee
mesh_terms: D000818:Animals; D001549:Benzamides / Q000138:chemical synthesis* / Q000378:metabolism; D001921:Brain / Q000000981:diagnostic imaging* / Q000378:metabolism; D060326:Chemistry Techniques, Synthetic; D008297:Male; D049268:Positron-Emission Tomography / Q000379:methods*; D011759:Pyrrolidines / Q000138:chemical synthesis* / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D017448:Receptors, Dopamine D2 / Q000378:metabolism; D050637:Receptors, Dopamine D3 / Q000378:metabolism
chemical_list: D001549:Benzamides; C585529:N-((2-pyrolidinyl)methyl)-2,3-dimethoxy-5-(3'-fluoropropyl)benzamide; D011759:Pyrrolidines; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; C574003:fallypride
references.citation: Synapse. 2011 Aug;65(8):724-32
references.pmid: 21132811
references.citation: J Pharmacol Exp Ther. 2005 Oct;315(1):80-90
references.pmid: 16014571
references.citation: Bioorg Med Chem. 2007 Nov 1;15(21):6819-29
references.pmid: 17765546
references.citation: Pharmacol Rev. 2011 Mar;63(1):182-217
references.pmid: 21303898
references.citation: Synapse. 2002 Dec 1;46(3):170-88
references.pmid: 12325044
references.citation: Curr Pharm Des. 2003;9(8):673-96
references.pmid: 12570798
references.citation: Phys Med Biol. 2009 May 7;54(9):2885-99
references.pmid: 19384008
references.citation: Bioorg Med Chem. 2008 Jul 1;16(13):6467-73
references.pmid: 18534857
references.citation: Nucl Med Biol. 2004 Apr;31(3):303-11
references.pmid: 15028242
references.citation: Synapse. 2011 Aug;65(8):778-87
references.pmid: 21218455
references.citation: Synapse. 2009 May;63(5):378-89
references.pmid: 19173265
references.citation: Bioorg Med Chem. 2004 Jan 2;12(1):95-102
references.pmid: 14697774
references.citation: Curr Pharm Des. 2003;9(8):643-71
references.pmid: 12570797
references.citation: Nucl Med Biol. 1999 Jul;26(5):519-27
references.pmid: 10473190
references.citation: Eur J Neurosci. 2002 Feb;15(3):449-57
references.pmid: 11876772
references.citation: Nucl Med Biol. 1995 Apr;22(3):283-96
references.pmid: 7627142
references.citation: J Med Chem. 1996 Oct 11;39(21):4233-7
references.pmid: 8863800
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 1998 Feb;22(2):397-410
references.pmid: 9608609
references.citation: Biol Psychiatry. 2010 Aug 15;68(4):392-9
references.pmid: 20599188